Dare Bioscience Inc (NASDAQ:DARE) — Market Cap & Net Worth
Market Cap & Net Worth: Dare Bioscience Inc (DARE)
Dare Bioscience Inc (NASDAQ:DARE) has a market capitalization of $30.28 Million ($30.28 Million) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #23801 globally and #5085 in its home market, demonstrating a 8.33% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Dare Bioscience Inc's stock price $2.08 by its total outstanding shares 14559502 (14.56 Million). Review Dare Bioscience Inc total liabilities to assess the company's total debt and financial obligations.
Dare Bioscience Inc Market Cap History: 2015 to 2026
Dare Bioscience Inc's market capitalization history from 2015 to 2026. Data shows change from $4.89 Billion to $30.28 Million (-39.11% CAGR).
Index Memberships
Dare Bioscience Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.00% | #684 of 976 |
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.00% | #2255 of 3165 |
Weight: Dare Bioscience Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Dare Bioscience Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Dare Bioscience Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
27.28x
Dare Bioscience Inc's market cap is 27.28 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.24 Billion | $766.00K | -$39.30 Million | 1615.31x | N/A |
| 2021 | $349.43 Million | $10.00 Million | -$38.70 Million | 34.94x | N/A |
| 2022 | $145.01 Million | $10.00 Million | $406.80 Million | 14.50x | 0.36x |
| 2023 | $53.99 Million | $2.81 Million | -$30.16 Million | 19.23x | N/A |
| 2024 | $45.43 Million | $9.78K | -$4.05 Million | 4642.85x | N/A |
| 2025 | $28.10 Million | $1.03 Million | -$13.40 Million | 27.28x | N/A |
Competitor Companies of DARE by Market Capitalization
Companies near Dare Bioscience Inc in the global market cap rankings as of June 18, 2026.
Key companies related to Dare Bioscience Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
Dare Bioscience Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Dare Bioscience Inc's market cap moved from $4.89 Billion to $ 30.28 Million, with a yearly change of -39.11%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $30.28 Million | +7.77% |
| 2025 | $28.10 Million | -38.14% |
| 2024 | $45.43 Million | -15.86% |
| 2023 | $53.99 Million | -62.77% |
| 2022 | $145.01 Million | -58.50% |
| 2021 | $349.43 Million | +49.25% |
| 2020 | $234.12 Million | +63.41% |
| 2019 | $143.27 Million | +15.41% |
| 2018 | $124.13 Million | -67.17% |
| 2017 | $378.08 Million | -69.44% |
| 2016 | $1.24 Billion | -74.71% |
| 2015 | $4.89 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Dare Bioscience Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $30.28 Million USD |
| MoneyControl | $30.28 Million USD |
| MarketWatch | $30.28 Million USD |
| marketcap.company | $30.28 Million USD |
| Reuters | $30.28 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Dare Bioscience Inc
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of… Read more